Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
YOLT-201 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
YOLT-201: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Bone marrow derived mesenchymal stem cell therapy (Taiwan Bio Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Bone marrow derived mesenchymal stem cell therapy (Taiwan Bio Therapeutics): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers.
8 min read
Cytomegalovirus peptide vaccine(City of Hope National Medical Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Cytomegalovirus peptide vaccine(City of Hope National Medical Center): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical.
8 min read
BI-771716 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
BI-771716: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
VSJ-110 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
VSJ-110: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
MC-225 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
MC-225: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
AUR-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
AUR-101: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
CNSI-Fe Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
CNSI-Fe: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
DM-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
DM-101: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
NTRX-07 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
NTRX-07: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
PXS-5505 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
PXS-5505: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
PRI-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
PRI-002: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.